Rule 2.9 Announcement - update

RNS Number : 6550Y
Integumen PLC
10 September 2020
 

AIM share code: SKIN

10 September 2020

 

Integumen PLC

 

("Integumen" or "Company")

 

 

Rule 2.9 Announcement - update

 

In accordance with Rule 2.9 of the Code:

Integumen confirms that, as at the date of this announcement, it has 1,131,431,426 ordinary shares of 0.01 pence each in issue and admitted to trading on AIM under the International Securities Identification Number ("ISIN") GB00BYWJ6269.

In addition, there are 46,277,142 unlisted warrants, with an exercise price of 2.0 pence per ordinary share, and an exercise period until 2 May 2021. These warrants are freely transferable and were issued on 2 May 2019.

In addition, there are 4,400,001 unlisted warrants, with an exercise price of 1.5 pence per ordinary share, and an exercise period until 5 January 2023. These warrants are freely transferable and were issued on 5 January 2018.

For further information please contact:

Integumen plc

Gerard Brandon, CEO

+44 (0) 7340 055 648




SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974




Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/Zoe Alexander

+44 (0) 20 3657 0050




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RTTFLFEFATIILII
UK 100

Latest directors dealings